For the complete documentation index, see llms.txt. This page is also available as Markdown.

Drug Extension Authoring

Model-Driven and Scalable Authoring

Drug extension content is not typically authored manually on a concept-by-concept basis. Instead, it is derived from existing national drug dictionaries using a structured and scalable process.

This approach is comparable to the development of terminologies such as LOINC, where content is generated based on combinations of well-defined attributes.

Process

1

Mapping Atomic Components

The process begins with mapping the atomic elements of the local drug dictionary to SNOMED CT and related standards. These include:

  • substances (active ingredients)

  • dose forms

  • units of measure

  • strength representations

SNOMED CT aligns with EDQM (European Directorate for the Quality of Medicines) standards for dose forms. Where local dictionaries also use EDQM, this significantly facilitates mapping and interoperability.

2

Deriving Drug Concepts

Once atomic elements are mapped, higher-level drug concepts are generated based on combinations identified in the local dictionary.

These include:

  • Medicinal Products (MP)

  • Medicinal Product Forms (MPF)

  • Clinical Drugs (CD)

  • Real Clinical Drugs (RCD)

  • Packaged Clinical Drugs (PCD)

  • Real Packaged Clinical Drugs (RPCD)

Concepts are typically created algorithmically, using rules derived from the SNOMED CT concept model.

3

Reuse and Gap Filling

During concept generation:

  • Existing concepts in the International Edition (MP, MPF, CD) should be reused wherever available

  • Missing concepts are created in the national extension

  • These missing concepts may later be submitted for promotion to the International Edition

This ensures consistency while allowing extensions to meet immediate national requirements.

4

Validation and Refinement

The generation process is typically implemented as:

  • an automated bulk creation process

  • followed by manual review and quality assurance

This hybrid approach balances scalability with clinical and terminological accuracy.

Typical Authoring Challenges

Drug extension development involves several common challenges, including:

  • Variations in ingredient representation across local dictionaries

  • Limited granularity in source data (e.g. missing strength or form details)

  • Rounding rules for strength normalization

  • Non-normalized strength expressions, including numerator/denominator inconsistencies

  • Differences in units of measure and representation conventions

Addressing these challenges requires careful normalization and alignment with the SNOMED CT concept model.

Provide Feedback